Browse ST3GAL6

Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Single-pass type II membrane protein
Domain PF00777 Glycosyltransferase family 29 (sialyltransferase)
Function

Involved in the synthesis of sialyl-paragloboside, a precursor of sialyl-Lewis X determinant. Has a alpha-2,3-sialyltransferase activity toward Gal-beta1,4-GlcNAc structure on glycoproteins and glycolipids. Has a restricted substrate specificity, it utilizes Gal-beta1,4-GlcNAc on glycoproteins, and neolactotetraosylceramide and neolactohexaosylceramide, but not lactotetraosylceramide, lactosylceramide or asialo-GM1.

> Gene Ontology
 
Biological Process GO:0001573 ganglioside metabolic process
GO:0001574 ganglioside biosynthetic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0006643 membrane lipid metabolic process
GO:0006664 glycolipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006672 ceramide metabolic process
GO:0006687 glycosphingolipid metabolic process
GO:0006688 glycosphingolipid biosynthetic process
GO:0006790 sulfur compound metabolic process
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009247 glycolipid biosynthetic process
GO:0009311 oligosaccharide metabolic process
GO:0018146 keratan sulfate biosynthetic process
GO:0018196 peptidyl-asparagine modification
GO:0018279 protein N-linked glycosylation via asparagine
GO:0030148 sphingolipid biosynthetic process
GO:0030203 glycosaminoglycan metabolic process
GO:0042339 keratan sulfate metabolic process
GO:0043413 macromolecule glycosylation
GO:0044272 sulfur compound biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0046467 membrane lipid biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0070085 glycosylation
GO:0070741 response to interleukin-6
GO:0071354 cellular response to interleukin-6
GO:0097503 sialylation
GO:1903509 liposaccharide metabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0003836 beta-galactoside (CMP) alpha-2,3-sialyltransferase activity
GO:0008373 sialyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0052798 beta-galactoside alpha-2,3-sialyltransferase activity
Cellular Component GO:0030173 integral component of Golgi membrane
GO:0031228 intrinsic component of Golgi membrane
GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
> KEGG and Reactome Pathway
 
KEGG hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series
hsa01100 Metabolic pathways
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022854: Keratan sulfate biosynthesis
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912420: Pre-NOTCH Processing in Golgi
R-HSA-4085001: Sialic acid metabolism
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-446219: Synthesis of substrates in N-glycan biosythesis
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ST3GAL6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ST3GAL6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ST3GAL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.2530.0145
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.8830.43
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8070.612
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1430.635
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1530.907
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1320.936
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4080.414
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2680.892
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5610.797
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0020.999
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0320.491
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1990.206
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ST3GAL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST3GAL6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST3GAL6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST3GAL6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST3GAL6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ST3GAL6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ST3GAL6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolST3GAL6
NameST3 beta-galactoside alpha-2,3-sialyltransferase 6
Aliases ST3GALVI; SIAT10; sialyltransferase 10 (alpha-2,3-sialyltransferase VI); CMP-NeuAc:beta-galactoside alpha-2, ......
Chromosomal Location3q12.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ST3GAL6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.